Arax Advisory Partners’s Mereo BioPharma MREO Stock Holding History

Arax Advisory Partners’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85K	Buy	5,819 +1,819	+45%	+$546	﹤0.01%	4831
2026 Q1	$1.32K	Hold	4,000	–	–	﹤0.01%	3223
2025 Q4	$1.67K	Hold	4,000	–	–	﹤0.01%	3326
2025 Q3	$8.24K	Hold	4,000	–	–	﹤0.01%	2679
2025 Q2	$10.8K	Hold	4,000	–	–	﹤0.01%	1925
2025 Q1	$9K	Hold	4,000	–	–	﹤0.01%	1597
2024 Q4	$14K	Hold	4,000	–	–	﹤0.01%	1361
2024 Q3	$16.4K	Hold	4,000	–	–	﹤0.01%	1164
2024 Q2	$14.4K	Hold	4,000	–	–	﹤0.01%	1098
2024 Q1	$13.2K	Hold	4,000	–	–	﹤0.01%	735
2023 Q4	$9.24K	Hold	4,000	–	–	﹤0.01%	772
2023 Q3	$5.16K	Hold	4,000	–	–	﹤0.01%	870
2023 Q2	$5.28K	Hold	4,000	–	–	﹤0.01%	855
2023 Q1	$2.83K	Hold	4,000	–	–	﹤0.01%	951
2022 Q4	$3K	Hold	4,000	–	–	﹤0.01%	899
2022 Q3	$3K	Hold	4,000	–	–	﹤0.01%	916
2022 Q2	$4K	Hold	4,000	–	–	﹤0.01%	831
2022 Q1	$4K	Hold	4,000	–	–	﹤0.01%	835
2021 Q4	$6K	Hold	4,000	–	–	﹤0.01%	742
2021 Q3	$10K	Buy	+4,000	New	+$10.6K	﹤0.01%	643

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Arax Advisory Partners's MREO Position: Q2 2026 in Review

Arax Advisory Partners increased its Mereo BioPharma (MREO) stake by 45% in Q2 2026, buying an estimated $546 and bringing the position to 5,819 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.

Arax Advisory Partners first reported a position in MREO in Q3 2021 and has held it in 20 quarters since. The position peaked at $16.4K in Q3 2024. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Arax Advisory Partners held 5,819 shares of Mereo BioPharma worth $1.85K as of Q2 2026.
Arax Advisory Partners bought 1,819 Mereo BioPharma shares in Q2 2026, an estimated $546.
Mereo BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4831 holding.
Arax Advisory Partners first reported a position in Mereo BioPharma in Q3 2021 and has held it in 20 quarters since.
Arax Advisory Partners's Mereo BioPharma position peaked at $16.4K in Q3 2024.
60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.